CBD efficacy in human DLBCL and MCL | 58233
Journal of Clinical and Cellular Immunology

Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

CBD efficacy in human DLBCL and MCL

Joint Event on Annual Congress on Cellular Therapies, Cancer, Stem Cells and Bio Medical Engineering & 5th International Conference on Pain Medicine and Pain Management

October 17-18, 2018 | New York, USA

Tori Strong

Vyripharm Biopharmaceuticals, USA

Posters & Accepted Abstracts: J Clin Cell Immunol

Abstract :

CBD Efficacy in Human DLBCL and MCL: Diffuse Large B-Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL) represent the most common and most aggressive forms of Non-Hodgkin Lymphoma (NHL) respectively; where DLBCL are characterized in two gene expressing groups: germinal center B-Cell-like (GBC) and aggressive activated B-cell like (ABC). Previous work has demonstrated CB1 antagonists as potential therapeutics for both DLBCL and MCL. Cannabidiol (CBD) is a natural cannabinoid analog that has mixed affinity across CB1 and CB2 receptors; known in the literature as a CB1 antagonist. Our previous work has demonstrated that CB1 antagonists have activity against DLBCL cell lines. Our study is aimed at demonstrating whether CBD has activity in DLBCL and MCL cell lines. Cells from representative DLBCL and MCL cell lines were plated at 5,000 cells per well. The cells were incubated for 72 hours in 20 μL medium with 10% FBS and varied concentrations of CBD or Dimethylsulfoxide (DMSO) vehicle. Viability assays were conducted using Celltiter-Glo Luminescent Cell Viability Assay. Experiments were performed 2-3 times independently with each concentration tested in triplicate. In vitro studies were done to determine the efficacy of CBD in DLBCL (GCB and ABC), as well as MCL. GCB-DLBCL, aggressive ABC-DLBCL and MCL cell lines treated with CBD showed similar patterns of reduction in viability. Most cell lines dropped dramatically in viability at concentrations of 10μM or greater with most cell lines at 0% of control at concentrations of 50μM.

Biography :

Tori Strong has completed his PhD from the University of Texas Medical Branch at Galveston. He is the director of Intellectual Property and Technology at Vyripharm Biopharmaceuticals, a premier biotech organization. He has served as a Patent Examiner for the USPTO and is now directly involved in the technology development to commercialization which includes strategies of building intellectual properly.